Brokerages Set Calyxt Inc (CLXT) PT at $21.05

Share on StockTwits

Calyxt Inc (NASDAQ:CLXT) has earned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $20.85.

Several equities research analysts recently weighed in on CLXT shares. Zacks Investment Research downgraded shares of Calyxt from a “buy” rating to a “hold” rating in a research note on Monday, November 19th. Goldman Sachs Group started coverage on shares of Calyxt in a research note on Friday, September 7th. They set a “neutral” rating and a $18.00 target price on the stock. Citigroup cut their target price on shares of Calyxt from $19.00 to $13.00 and set a “neutral” rating on the stock in a research note on Monday, November 19th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $27.00 target price on shares of Calyxt in a research note on Thursday, November 15th.

Shares of CLXT opened at $10.37 on Wednesday. Calyxt has a fifty-two week low of $10.21 and a fifty-two week high of $27.23. The company has a debt-to-equity ratio of 0.17, a quick ratio of 15.01 and a current ratio of 15.01.

Calyxt (NASDAQ:CLXT) last announced its earnings results on Wednesday, November 14th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06. Calyxt had a negative net margin of 6,256.67% and a negative return on equity of 33.08%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.50 million. On average, analysts expect that Calyxt will post -0.93 earnings per share for the current fiscal year.

In other Calyxt news, insider Manoj Sahoo sold 2,521 shares of the stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $14.84, for a total value of $37,411.64. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Daniel F. Voytas sold 4,083 shares of the stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $13.00, for a total transaction of $53,079.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,553 shares of company stock worth $303,275. Insiders own 2.80% of the company’s stock.

Several large investors have recently made changes to their positions in the business. Millennium Management LLC purchased a new position in shares of Calyxt in the 2nd quarter valued at $582,000. FMR LLC grew its position in shares of Calyxt by 40.2% in the 2nd quarter. FMR LLC now owns 4,799,299 shares of the company’s stock valued at $89,603,000 after buying an additional 1,375,899 shares during the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Calyxt in the 2nd quarter valued at $186,000. Laurion Capital Management LP purchased a new position in shares of Calyxt in the 2nd quarter valued at $1,150,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Calyxt in the 2nd quarter valued at $5,601,000. 28.30% of the stock is currently owned by institutional investors.

Calyxt Company Profile

Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, improved oil composition canola, herbicide tolerant canola, improved quality alfalfa and herbicide tolerant alfalfa, late blight resistant potatoes, cold storable/reduced browning potatoes, improved protein composition soybeans, drought tolerant soybeans, herbicide tolerant soybeans, and improved yield soybeans.

Featured Article: Systematic Risk

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.